Asian Pacific Journal of Cancer Care (Jul 2023)

Breast Cancer Treatment and Outcomes in Nigeria: A Systematic Review and Meta-analysis

  • Agodirin Olayide,
  • Aremu Isiaka,
  • Rahman Ganiyu,
  • Olatoke Samuel,
  • Akande Halimat,
  • Olasehinde Olalekan,
  • Olaogun Julius,
  • Romanoff Anya

DOI
https://doi.org/10.31557/apjcc.2023.8.3.591-598
Journal volume & issue
Vol. 8, no. 3
pp. 591 – 598

Abstract

Read online

Background: Nigeria has one of the highest age-standardized breast cancer (BC) mortality rates globally and the highest in Africa. Late presentation and diagnosis have been studied extensively as causes of high BC morbidity and mortality, while treatment and outcomes are under-reported. We aggregated data on BC treatment and outcomes in Nigeria to identify gaps in research, challenges, and potential targets for future interventions. Methods: Articles on female BC management in Nigeria published between 2011 and 2021 were reviewed for the prevalence of different treatment modalities and outcomes. The meta-analytical procedure was a random effect model. Results: We identified 15 articles that reported on the treatment and outcomes of 3857 BC patients. The most prevalent treatment modality was chemotherapy alone. The probability of receiving each treatment modality was 85% (95% CI 66-97) for chemotherapy, 62% (95% CI 51-73) for surgery, and 31% (95% CI 8-59) for radiotherapy. Multimodality treatment, including chemotherapy, surgery, and radiation, was administered to 24% (95% CI 10-43) of patients. In studies with available data, nearly half of patients who initiated chemotherapy did not complete the recommended number of doses or received treatments at irregular intervals. The radiotherapy utilization was five times higher when patients received treatment in centers with radiation facilities. Overall survival estimates were 80% at one year, 43% at two years, and 32% at five years. Patients with early-stage (AJCC I/II) disease survived longer, with a 5-year survival difference of 32% compared to patients with late-stage (AJCC III/IV) disease. Patients receiving multimodality therapy survived longer. Three-year survival for patients who received chemotherapy, surgery and radiotherapy was 68%. Whereas it was 43% in patients who received chemotherapy and surgery only. Conclusion: Improving access to complete systemic therapy, surgery, and radiation for breast cancer patients in Nigeria is imperative and should be the target of future interventions.

Keywords